Skip to Main Content
Our Commitment to Diversity

K&L Gates Triage: 340B Program: A Conversation with Chris Hatwig, Apexus President Part 1

Share via LinkedIn
Share via Twitter
Share via Facebook
Date: 4 December 2018
Triage

This is the first episode in K&L Gates’ three-part series on the 340B Program with Chris Hatwig, President of Apexus, LLC. Apexus serves as HRSA’s Prime Vendor in administering the 340B Program, including by publishing guidance and compliance tools to assist stakeholders in running their 340B operations. This first episode discusses best practices for resolving non-compliance under the 340B Program, how to determine whether an issue is a “material breach” of 340B requirements, HRSA’s self-disclosure process, and some of the most common compliance issues that arise.

About Triage
Triage: Rapid Legal Lessons for Busy Health Care Professionals has been created by K&L Gates to convey information about developments in health law through short podcasts.

If you work in the health care industry, you have grown accustomed to frequent changes in laws and regulations. On some days, it may seem like an insurmountable task to keep up with every change, especially as a new presidential administration and new policies take shape.

The K&L Gates Health Care Practice will regularly create Triage podcasts to help you learn about the latest developments in health law. Our lawyers will identify the most important changes and analyze the impact of these changes on our clients.

Catch-up on past episodes by visiting our Triage program page.

Subscribe to Triage via your favorite podcast app to have our episodes delivered directly to you as they become available.

    Listen on Google Play Music

Find more items tagged as: Health Care and FDA
Return to top of page

Email Disclaimer

We welcome your email, but please understand that if you are not already a client of K&L Gates LLP, we cannot represent you until we confirm that doing so would not create a conflict of interest and is otherwise consistent with the policies of our firm. Accordingly, please do not include any confidential information until we verify that the firm is in a position to represent you and our engagement is confirmed in a letter. Prior to that time, there is no assurance that information you send us will be maintained as confidential. Thank you for your consideration.

Accept Cancel